EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Baseline basophil activation and early suppression is associated with clinical outcome after peanut sublingual immunotherapy

Jessica R Humphrey, Rishu Guo, Xiaohong Yue, Corinne A Keet, Yamini V Virkud, J Andrew Bird, A Wesley Burks, Edwin H Kim, Johanna M Smeekens, Michael D Kulis

Journal of Allergy and Clinical Immunology · 2025

DOI: 10.1016/j.jaci.2025.04.010 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Jessica R Humphrey und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC; Curriculum in Toxicology and Environmental Medicine, Univ…. Hauptthemen laut MEDLINE: Basophils, Peanut Hypersensitivity, Sublingual Immunotherapy, Arachis. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCCIH NIH HHS, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Sublingual immunotherapy (SLIT) was recently shown to safely induce desensitization and remission of peanut allergy in 1- to 4-year-old children. OBJECTIVE: Basophil activation has been shown to be suppressed in allergen-specific immunotherapy. We aimed to evaluate the timing of basophil suppression during peanut SLIT and its impact on clinical outcomes. METHODS: A total of 50 children with peanut allergy were enrolled in a peanut SLIT trial and randomized to active peanut or placebo SLIT for 36 months followed by a 3-month avoidance period to evaluate remission. To measure basophil activation by CD63 and CD203c, blood was collected at baseline and again at 12, 24, 36, and 39 months. RESULTS: For participants receiving peanut SLIT, basophil activation based on CD63 expression was significantly reduced by 12 months and continued to decrease throughout peanut SLIT, whereas CD63 activation in participants receiving placebo remained unchanged from 0 to 36 months. CD203c expression remained unchanged for both peanut SLIT and placebo participants throughout the trial. Actively treated participants who achieved remission had lower CD63 expression at baseline and significant suppression of CD63 expression by 12 months, whereas participants who failed treatment had higher CD63 expression at baseline and lack of suppression by 12 months. Lower basophil activation in those achieving remission, compared to those who failed treatment, remained present for up to 3 years. CONCLUSIONS: Following peanut SLIT, participants who achieved remission had significantly suppressed basophil activation by 12 months compared to unsuccessful participants who were not desensitized, suggesting that early suppression of basophils may be indicative of peanut SLIT efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BasophilsPeanut HypersensitivitySublingual ImmunotherapyArachisAllergensHumansChild, PreschoolMaleFemaleTetraspanin 30InfantTreatment OutcomePyrophosphatasesPhosphoric Diester Hydrolases

Stichwörter der Autor:innen

Peanut allergySLITbasophil activationfood allergysublingual immunotherapy

Substanzen

Tetraspanin 30AllergensPyrophosphatasesENPP3 protein, humanCD63 protein, humanPhosphoric Diester Hydrolases

Autor:innen und Institutionen

  • Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC; Curriculum in Toxicology and Environmental Medicine, University of North Carolina School of Medicine, Chapel Hill, NC. Electron…
  • Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
  • Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Tex.
  • Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC; Curriculum in Toxicology and Environmental Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.

Förderung

  • NCI NIH HHS
  • NCCIH NIH HHS
  • NIEHS NIH HHS
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • Food Allergy Research & Education
  • University of North Carolina
  • National Institute of Environmental Health Sciences

Zitieren

APA

Humphrey, J. R., Guo, R., Yue, X., Keet, C. A., Virkud, Y. V., Bird, J. A., Burks, A. W., Kim, E. H., Smeekens, J. M., & Kulis, M. D. (2025). Baseline basophil activation and early suppression is associated with clinical outcome after peanut sublingual immunotherapy. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2025.04.010

Vancouver

Humphrey JR, Guo R, Yue X, Keet CA, Virkud YV, Bird JA, et al. Baseline basophil activation and early suppression is associated with clinical outcome after peanut sublingual immunotherapy. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2025.04.010

BibTeX
@article{Humphrey2025,
  author = {Humphrey, Jessica R and Guo, Rishu and Yue, Xiaohong and Keet, Corinne A and Virkud, Yamini V and Bird, J Andrew and Burks, A Wesley and Kim, Edwin H and Smeekens, Johanna M and Kulis, Michael D},
  title = {Baseline basophil activation and early suppression is associated with clinical outcome after peanut sublingual immunotherapy},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  doi = {10.1016/j.jaci.2025.04.010}
}
Kostenlos starten →